Osaka Soda Co (4046) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
18 May, 2026Executive summary
Net sales for the nine months ended December 31, 2024, rose 6.3% year-over-year to ¥74,650 million, with operating profit up 40.0% to ¥10,639 million and profit attributable to owners of parent up 49.9% to ¥7,940 million.
Recovery in the Japanese economy supported by improved employment and consumer spending, but challenges persisted from high raw material costs, global conflicts, and weak Chinese real estate.
Strategic focus on strengthening core businesses, new product development, and sustainability management under the medium-term plan.
Financial highlights
Gross profit increased to ¥21,985 million from ¥18,137 million year-over-year.
Ordinary profit rose 36.1% year-over-year to ¥11,700 million.
Basic earnings per share for the period was ¥62.59, calculated post-stock split.
Comprehensive income was ¥7,714 million, nearly flat year-over-year.
Equity-to-asset ratio improved to 74.4% from 72.9% at the previous fiscal year-end.
Outlook and guidance
Full-year forecast unchanged: net sales of ¥103,000 million (+8.9% YoY), operating profit of ¥16,000 million (+52.5%), ordinary profit of ¥16,800 million (+39.9%), and profit attributable to owners of parent of ¥11,500 million (+50.3%).
Projected basic earnings per share for the year ending March 31, 2025, is ¥90.65 post-stock split.
Latest events from Osaka Soda Co
- Operating profit jumped 41.7% on 7.6% higher sales, led by healthcare and functional chemicals.4046
Q2 202518 May 2026 - Profits and sales rose on strong healthcare and chemicals demand; stock split set for October.4046
Q1 202518 May 2026 - Profits surged on healthcare growth and supply recovery, with record highs forecast for FY2025 and FY2026.4046
Q4 202518 May 2026 - Profits rose sharply despite lower sales, with upward guidance and enhanced shareholder returns.4046
Q2 202618 May 2026 - First-quarter profit rose 9.4% year-on-year, driven by healthcare and basic chemicals growth.4046
Q1 202618 May 2026 - Operating profit surged 21.6% and net profit rose 34.0% despite a 1.3% sales decline.4046
Q3 202618 May 2026 - Record profits and sales driven by Basic chemicals and Healthcare, with robust cash flow and new growth plans.4046
Q4 202618 May 2026